Carola Schröder, Senior Vice President, Octapharma Biopharmaceuticals

From a small idea to a novel product: highest quality and constant innovation is our driving force.

R&D Recombinant

Octapharma's R&D Recombinant Group is dedicated to:

  • The development of therapeutic human recombinant products 
  • Clinical upscale and pharmaceutical scale production

Recombinant proteins are produced in cultured human cells. Human recombinant proteins produced in human cell lines show identical properties to the same protein derived directly from human tissues and blood. They are therefore expected to show improved tolerance in patients compared to currently available hamster cell-derived recombinant products.

 

Octapharma’s first recombinant product, blood clotting Factor VIII (hcl-rFVIII), is currently in Clinical Phase III, with other research projects in different stages of development.